Maha Noor Mian

Maha Noor Mian

Auto-generated profile, based on publicly available information

Maha Noor Mian

Suffolk University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2021 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MEMitch Earleywine
Mitch Earleywine
LULuna F Ueno
Luna F Ueno
MMMaha N Mian
Maha N Mian
BABrianna R Altman
Brianna R Altman
Background: Despite tetrahydrocannabinol (THC)’s reputation for creating dramatic effects at high doses, empirical work rarely addresses cannabis’s impact on subjective responses common to the tryptamine psychedelics. We focused on these effects because they have preceded and covaried with the therapeutic impact of psilocybin in previous work. Aims: The current study examined if self-reported responses to cannabis products might parallel those found in clinical trials of psilocybin administration. We also investigated if measures of demographics and cannabis use might correlate with these responses. Methods: Participants reported the subjective effect of their highest THC experience using 27 items that assess oceanic boundlessness, a correlate of mystical experiences. They also answered infrequency items and questions on demographics and cannabis consumption. Results: In an effort to address concerns about replication, we divided respondents who passed infrequency items into two random samples. Self-reported “breakthrough” experiences were significantly greater than zero but significantly lower than those reported in randomized clinical trials of psilocybin (17–19% vs. 59%). Total scores covaried with perceived dosages of THC, but only in one sample. Heavier users of cannabis reported lower scores. Conclusions: Self-report data suggest that high doses of cannabis can create subjective effects comparable to those identified in trials of psilocybin that precede relief from cancer-related distress, treatment-resistant depression, alcohol problems, and cigarette dependence. Given the disparate mechanisms of action, comparing THC-induced to psilocybin-induced effects might improve our understanding of the mechanisms underlying subjective experiences. This work might also support the development of a cannabis-assisted psychotherapy comparable to psilocybin-assisted psychotherapy.

30 September 2019 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
MMMaha N. Mian
Maha N. Mian
BAB. R. Altman
B. R. Altman
MEM. Earleywine
M. Earleywine
Ayahuasca, a plant-based hallucinogen that serves as a spiritual medicine in South America, has improved depression in at least one placebo-controlled clinical trial. Case studies suggest that dramatic behavioral changes often follow the Ayahuasca ceremony, but most explanations of antidepressant effects focus on changes in mindfulness. This study investigated whether both mindfulness and behavioral activation might contribute to these anti-depressant effects. We surveyed individuals (N = 152) about their changes in depressive symptoms, behavioral activation, and mindfulness after an Ayahuasca experience. Mindfulness was strongly associated with reduced depression severity (r = − .670, p < .001), while behavioral activation was moderately linked (r = − .474, p < .001). Changes in depressive symptoms (Center for Epidemiological Sciences Depression Short Form [CES-D-10]) covaried with subscales from the Five Facet Mindfulness Questionnaire [FFMQ] and Experiences Questionnaire [EQ], confirming previous findings (β = −.57, 95% CI −5.70, −3.25), p < .001). In addition, a modification of the Behavioral Activation for Depression Scale-Short Form [BADS-SF] accounted for significant unique variance in the improvements in depression (β = − .16, 95% CI −6.32, −0.08), p < .05). Changes in behavioral activation likely serve as a mechanism underlying Ayahuasca’s antidepressant effects. Future clinical trials could benefit from tracking behavioral activation.

12 January 2021 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
LULuna F. Ueno
Luna F. Ueno
MMMaha N. Mian
Maha N. Mian
BABrianna R. Altman
Brianna R. Altman
EGEric Giandelone
Eric Giandelone
MLMike Luce
Mike Luce
MEMitch Earleywine
Mitch Earleywine
Cannabis use varies with age and gender, but less is known regarding specific product choices. Previous work suggests that older adults are inclined to stick to the more “classic” and familiar, while “novel” products are more likely to appeal to younger populations. We examined cross-sectional, retrospective data to determine whether the type of cannabis products used varied according to participant age (N = 1406, 71.3% female). The extensive list of products included: loose flower, pre-rolled joints, edibles, concentrates, oil vaporizers (vape pens), dry vaporizers, tinctures, topicals, and ingestible oils. Overall, rates of use for cannabis-infused ingestible oils, topicals, and tinctures are the lowest and show no age or gender-related differences. In contrast, the use of pre-rolled joints, vape pens, and edibles tends to decrease with age. Loose flower and dry vaporizer use also decrease with age, although less consistently. These age-related differences in product choices can facilitate prevention and treatment efforts toward specific populations. While harm-reduction efforts targeting loose flower and edible products would benefit all age groups, those targeting concentrates might focus only on younger users. On the other hand, learning about concentrates might be beneficial for older medical users due to their larger THC doses and rapid onset.

20 July 2023 in Addictive Behaviors
Verified
Journal Article
Closed access
MMMaha N. Mian
Maha N. Mian
TFTara R Foti
Tara R Foti
AGAndrea Green
Andrea Green
EIEsti Iturralde
Esti Iturralde
AAAndrea Altschuler
Andrea Altschuler
KYKelly C. Young-Wolff
Kelly C. Young-Wolff

30 December 2022 in Addiction Research & Theory
Verified
Journal Article
Closed access
MMMaha N. Mian
Maha N. Mian
MEMitch Earleywine
Mitch Earleywine
Although savoring appears protective against cannabis problems, researchers have yet to apply it to reduce cannabis-related harms. Study I surveyed a large (N = 557, Mage = 36.9, 50.1% Male, 73% White) sample who rated a hypothetical savoring intervention as feasible and acceptable; those who savored more reported fewer cannabis problems, less use, and less intoxication. Study II, a pilot experiment (N = 26, Mage = 18, 34.6% Male, 42% White), randomly assigned participants to either a week-long savoring intervention (n = 15) or control group (n = 11). Savorers reported moderate to large decreases across time in cannabis use, amount consumed, and intoxication as well as increases in happiness and negative cannabis expectancies. Both studies suggest that savoring can reduce use and protect against negative outcomes. These preliminary findings suggest that further work to examine the efficacy of savoring as an intervention for substance use appears warranted.

22 November 2020 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
MMMaha N. Mian
Maha N. Mian
BABrianna R. Altman
Brianna R. Altman
LULuna F. Ueno
Luna F. Ueno
MEMitch Earleywine
Mitch Earleywine
Savoring has covaried inversely with cannabis problems and moderated the association between cannabis use and negative consequences related to use. Research has not yet addressed the acceptability of savoring interventions for cannabis users. The present study aimed to replicate the finding of savoring as a protective factor against problems for cannabis users. The second aim of the study was to examine preferences for a savoring intervention among problem-endorsing cannabis users. We sampled 447 (63.3% female) problem users who self-reported cannabis use, cannabis problems, savoring beliefs, and preferences for cannabis use interventions. On average, our sample reported using cannabis 4.7 days per week and 16.03 times per month, with men endorsing significantly more cannabis-related problems than women. Savoring did increase as problems decreased, but the moderator effect did not replicate. Problem cannabis users preferred a savoring intervention to a typical harm reduction intervention across all sampled demographics, with one notable exception: women were 1.73 times more likely to prefer a savoring intervention. Our findings confirmed that cannabis problems decrease as savoring increases and identified a preference for a savoring intervention among problem users.